Glycosylation is one of the most important posttranslational modifications of proteins and plays essential roles in various biological processes. Aberration in the glycan moieties of glycoproteins is associated with many diseases. It is especially critical to develop the rapid and sensitive methods for analysis of aberrant glycoproteins associated with diseases. Mass spectrometry (MS) has become a powerful tool for glycoprotein analysis. Especially, tandem mass spectrometry can provide highly informative fragments for structural identification of glycoproteins. This review provides an overview of the development of MS technologies and their applications in identification of abnormal glycoproteins and glycans in human serum to screen cancer biomarkers in recent years. © 2014 Liu et al.; licensee BioMed Central Ltd.
Liu, H., Zhang, N., Wan, D., Cui, M., Liu, Z., & Liu, S. (2014). Mass spectrometry-based analysis of glycoproteins and its clinical applications in cancer biomarker discovery. Clinical Proteomics. BioMed Central Ltd. https://doi.org/10.1186/1559-0275-11-14